Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

This is a single arm, open-label study. This study is indicated for moderate to severe active systemic lupus erythematosus. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products and our earlier disclosed clinical trials . 1\. Main research objectives: To evaluate the safety of metabolically armed CD19 CAR-T Cells in the treatment of moderate to severe active SLE. 2\. Secondary research objectives: 1. To evaluate the efficacy, pharmacokinetic (PK)/pharmacodynamic (PD) characteristics, and persistence of metabolically armored CD19 CAR-T cells for moderate to severe active SLE, and their relationship with the number of B cells. 2. To evaluate the effects of the concentration of autoimmune antibodies and complement after infusion of metabolically armed CD19 CAR-T Cells. 3. To further explore the feasibility and safety of CAR-T therapy regimens without lymphodepletion pretreatment.